La vendita allo scoperto per X4 Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di X4 Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

X4 Pharmaceuticals (NASDAQ:XFOR) Azioni, Report sulle vendite allo scoperto

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
<ul>
<li>Revenue growth to be in the range of 7 to 9 percent;
<ul>
<li>U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;</li>
<li>International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;</li>
</ul>
</li>
<li>Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.</li>
</ul>
Additional expectations include:
<ul>
<li>Adjusted operating income growth to be in the range of 5 to 6.5 percent;
<ul>
<li>U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;</li>
<li>International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;</li>
</ul>
</li>
<li>Interest expense to be in the range of $150 million to $170 million;</li>
<li>Adjusted effective tax rate of approximately 21 percent;</li>
<li>Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion;</li>
<li>Capital expenditures to be approximately $600 million; and</li>
<li>Weighted average diluted shares outstanding to be approximately 196 million.</li>
</ul>

Earnings

Large Cap

News

Guidance

Health Care

General

Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%

WIIM

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

McVey has agreed to remain as the Chairman of the Board of Directors of MarketAxess Limited, the Company's international holding company.

Management

MKTX

MarketAxess Founder And Executive Chairman Rick Mcvey To Retire At Year-End; Carlos Hernandez Elected As Next Chairman

The quarterly dividend of $0.55 per common share is payable November 29, 2024, to stockholders of record at the close of business on November 15, 2024.&nbsp;

Dividends

Cencora Declared A Quarterly Dividend Of $0.55 Per Common Share, An 8% Increase In Its Quarterly Dividend Rate From $0.51 Per Common Share

Kennametal Sees Q2 Revenues Of $480M-$500M Vs. $492.97M Estimate; And Adjusted EPS Of $0.20-$0.30 Vs. $0.27 Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.34 per share which beat the analyst consensus estimate of $3.22 by 3.73 percent. This is a 16.78 percent increase over earnings of $2.86 per share from the same period last year. The company reported quarterly sales of $79.05 billion which beat the analyst consensus estimate of $77.65 billion by 1.80 percent. This is a 14.70 percent increase over sales of $68.92 billion the same period last year.

Cencora Q4 2024 Adj EPS $3.34 Beats $3.22 Estimate, Sales $79.05B Beat $77.65B Estimate

Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.&nbsp;
Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.
 &nbsp;

CGI's Q4 Bookings Were $3.82B For A Book-To-Bill Ratio Of 104.4%

The Company now expects its fiscal 2024 organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%.&nbsp;

PRGO

Perrigo Now Expects FY24 Organic Net Sales And Reported Net Sales Outlooks Towards Lower End Of Its Previously Stated Ranges

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.26 by 11.54 percent. The company reported quarterly sales of $481.948 million which missed the analyst consensus estimate of $484.074 million by 100.00 percent. This is a 100.00 percent decrease over sales of $492.476 million the same period last year.

Earnings Beats

Earnings Misses

Kennametal Q1 2025 Adj. EPS $0.29 Beats $0.26 Estimate, Sales $481.948M Miss $484.074M Estimate

GPUS

Hyperscale Data Announced That It Plans To Issue A $16.25M Stated Value Special Dividend of 10% Series E Cumulative Redeemable Perpetual Preferred Stock

Perrigo Reaffirms FY24 Adjusted EPS Outlook Of $2.50 - $2.65, Est $2.57

CVS shares are trading higher following a Q3 revenue beat.

Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) reported quarterly losses of $(2.44) per share which missed the analyst consensus estimate of $(1.01) by 141.58 percent. The company reported quarterly sales of $1.335 billion which beat the analyst consensus estimate of $1.329 billion by 0.44 percent.

LINE

Lineage Q3 2024 GAAP EPS $(2.44) Misses $(1.01) Estimate, Sales $1.335B Beat $1.329B Estimate

CGI Q4 2024 Adj. EPS C$1.92 Beats C$1.91 Estimate, Sales C$3.660B Beat C$3.609B Estimate

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.82 by 1.22 percent. This is a 26.56 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.09 billion which missed the analyst consensus estimate of $1.13 billion by 3.29 percent. This is a 3.20 percent decrease over sales of $1.12 billion the same period last year.

Perrigo Q3 2024 Adj EPS $0.81 Misses $0.82 Estimate, Sales $1.09B Miss $1.13B Estimate

Transaction Details
Cencora will acquire RCA for approximately $4.6 billion in cash, subject to a customary working capital and net-debt adjustment. RCA's affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain predefined business objectives.

Cencora Has Agreed To Acquire Retina Consultants Of America From Webster Equity Partners For Approximately $4.6B In Cash

Benchmark analyst David Williams reiterates Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and maintains $40 price target.

AOSL

Benchmark Reiterates Buy on Alpha & Omega, Maintains $40 Price Target

MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.83 by 3.83 percent. The company reported quarterly sales of $206.715 million which beat the analyst consensus estimate of $206.245 million by 0.23 percent. This is a 19.99 percent increase over sales of $172.284 million the same period last year.

MarketAxess Holdings Q3 2024 GAAP EPS $1.90 Beats $1.83 Estimate, Sales $206.715M Beat $206.245M Estimate

CVS Health Q3 2024 Adj. EPS $1.09 Misses $1.53 Estimate, Sales $95.428B Beat $92.747B Estimate

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on X4 Pharmaceuticals (XFOR – Research Report). The associated p...

Buy Rating Affirmed for X4 Pharmaceuticals Amidst Clinical and Financial Strengths

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals (XFOR) has provided an update. X4 Pharmaceuticals, Inc. has released an updated corporate presentation, which is now available f...

X4 Pharmaceuticals Updates Corporate Presentation for Investors

X4 Pharmaceuticals Q2 2024 Earnings Preview

X4 Pharmaceuticals GAAP EPS of $0.45 beats by $0.46

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target ...

Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report), with a price...

X4 Pharmaceuticals (XFOR) Gets a Buy from Piper Sandler

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report), with a pric...

Stifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)

X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...

X4 Pharmaceuticals Unveils Corporate Presentation for Investors

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

XFOR

XFORW

Press Releases

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Markets

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Comments

X4 Pharmaceuticals

Vendite allo scoperto

X4 Pharmaceuticals (NASDAQ:XFOR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO